TB Research

Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1

Ragunathan P, Dick T, Grüber G

Antimicrobial agents and chemotherapy · 2022-04

Abstract

New drug targets and molecules with bactericidal activity are needed against the respiratory mycobacterial pathogen Mycobacterium abscessus. Employing a lead repurposing strategy, the antituberculosis compound GaMF1 was tested against M. abscessus. Whole-cell and ATP synthesis assays demonstrated that GaMF1 inhibits growth and kills M. abscessus by targeting the F-ATP synthase. GaMF1's anti-M. abscessus activity increased in combination with clofazimine, rifabutin, or amikacin. The study expands the repertoire of anti-M. abscessus compounds targeting oxidative phosphorylation.

MeSH terms

  • Humans
  • Tuberculosis
  • Adenosine Triphosphate
  • Enzyme Inhibitors
  • Anti-Bacterial Agents
  • Microbial Sensitivity Tests
  • Mycobacterium Infections, Nontuberculous
  • Mycobacterium abscessus